{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:55:24Z","timestamp":1776142524880,"version":"3.50.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Purpose<\/jats:title>\n The safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for prevention of chemotherapy-induced neutropenia (CIN) in patients undergoing oral chemotherapy remain unclear. This study aimed to investigate the safety and efficacy of PEG-rhG-CSF as primary prophylaxis for CIN in gastrointestinal (GI) cancer patients receiving combination chemotherapy regimens that include oral chemotherapy agents.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This is a prospective, single-center, open-label, exploratory, non-randomized controlled study. GI cancer patients was treated with intravenous oxaliplatin (130mg\/m\n 2<\/jats:sup>\n on day 1) combined with either oral capecitabine (1000mg\/m\n 2<\/jats:sup>\n ) or S\u22121 (an oral fluoropyrimidine combination of tegafur, gimeracil, and oteracil potassium; 40\u201360 mg) administered twice daily on days 1\u201314 of a 3\u2212week cycle. The treatment group received subcutaneous injection of PEG-rhG-CSF (6mg) 24 hours after oxaliplatin, while the control group received no primary prophylaxis. The primary endpoint was safety, and secondary endpoints included the incidence of CIN.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Between March 2022 and January 2023, 49 patients were screened, and 43 patients who completed at least two treatment cycles were included in the final analysis (26 in treatment group and 17 in control group). The overall adverse events (AEs) did not differ statistically (93.8% vs 100.0%,\n p<\/jats:italic>\n \u00a0=\u00a00.542). For grade \u2265 3 AEs, the incidence of neutropenia was significantly lower in the treatment group compared to the control group (3.1% vs 35.3%,\n p<\/jats:italic>\n \u00a0=\u00a00.005). No significant differences were observed in the rates of grade \u2265 3 thrombocytopenia (6.3% vs 17.6%,\n p<\/jats:italic>\n \u00a0=\u00a00.326) and leukopenia (3.1% vs 0.0%,\n p<\/jats:italic>\n \u00a0=\u00a01.000). Grade\u22652 CIN was significantly lower in the treatment group (25.0% vs. 76.5%,\n p<\/jats:italic>\n \u00a0&lt;\u00a00.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n In GI cancer patients on oral agents, primary PEG-rhG-CSF prophylaxis was well-tolerated and reduced grade \u22652 CIN, though randomized studies are needed.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial Registration<\/jats:title>\n \n https:\/\/www.chictr.org.cn<\/jats:ext-link>\n , identifier ChiCTR2100054854.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2026.1764358","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:21:17Z","timestamp":1776140477000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of PEG-rhG-CSF as primary prophylaxis for neutropenia in gastrointestinal cancer patients receiving combination chemotherapy including oral agents: a prospective, exploratory, non-randomized controlled study"],"prefix":"10.3389","volume":"16","author":[{"given":"Hui","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Oncology, Changzhi People\u2019s Hospital Affiliated to Changzhi Medical College","place":["Changzhi, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Shanxi Medical University","place":["Taiyuan, Shanxi, China"]},{"name":"Department of Oncology, Changzhi People\u2019s Hospital Affiliated to Changzhi Medical College","place":["Changzhi, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunyi","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changzhi People\u2019s Hospital Affiliated to Changzhi Medical College","place":["Changzhi, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changzhi People\u2019s Hospital Affiliated to Changzhi Medical College","place":["Changzhi, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changzhi People\u2019s Hospital Affiliated to Changzhi Medical College","place":["Changzhi, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangjun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changzhi People\u2019s Hospital Affiliated to Changzhi Medical College","place":["Changzhi, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changzhi People\u2019s Hospital Affiliated to Changzhi Medical College","place":["Changzhi, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changzhi People\u2019s Hospital Affiliated to Changzhi Medical College","place":["Changzhi, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changzhi People\u2019s Hospital Affiliated to Changzhi Medical College","place":["Changzhi, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suxia","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changzhi People\u2019s Hospital Affiliated to Changzhi Medical College","place":["Changzhi, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqing","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Changzhi People\u2019s Hospital Affiliated to Changzhi Medical College","place":["Changzhi, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gehong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, First Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changzhi People\u2019s Hospital Affiliated to Changzhi Medical College","place":["Changzhi, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, Nccn clinical practice guidelines in oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0041","article-title":"Nccn guidelines\u00ae insights: Rectal cancer, version 3.2024","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.annonc.2025.05.528","article-title":"Localised rectal cancer: Esmo clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Hofheinz","year":"2025","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102226","article-title":"Pan-Asian adapted esmo clinical practice guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer","volume":"9","author":"Shitara","year":"2024","journal-title":"ESMO Open"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12639","article-title":"The Chinese Society of Clinical Oncology (Csco): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update","volume":"45","author":"Wang","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12516","article-title":"The Chinese Society of Clinical Oncology (Csco): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01326","article-title":"Oxaliplatin-based adjuvant chemotherapy in older patients with stage iii colon cancer: An accent\/idea pooled analysis of 12 trials","volume":"42","author":"Gallois","year":"2024","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-024-01536-7","article-title":"Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage ii\/iii resectable gastric cancer (Resonance): A randomized, open-label, phase 3 trial","volume":"17","author":"Wang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa124","article-title":"Sex and adverse events of adjuvant chemotherapy in colon cancer: An analysis of 34\u2009640 patients in the accent database","volume":"113","author":"Wagner","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.11.005","article-title":"Impact of chemotherapy-induced neutropenia (Cin) and febrile neutropenia (Fn) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data","volume":"120","author":"Lalami","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25332","article-title":"Risk of mortality in patients with cancer who experience febrile neutropenia","volume":"116","author":"Lyman","year":"2010","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0086","article-title":"Treatment-related complications of systemic therapy and radiotherapy","volume":"5","author":"Jairam","year":"2019","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20230224-00076","article-title":"Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China (2023 edition)","volume":"45","author":"Jifeng","year":"2023","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0026","article-title":"Nccn guidelines\u00ae insights: Hematopoietic growth factors, version 1.2022","volume":"20","author":"Griffiths","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of pegfilgrastim","volume":"50","author":"Yang","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200504000-00011","article-title":"Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer","volume":"16","author":"Wenzel","year":"2005","journal-title":"Anticancer Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/cam4.5130","article-title":"Safety and efficacy of same-day administration of pegfilgrastim in patients receiving chemotherapy for gastrointestinal Malignancies","volume":"4","author":"Matera","year":"2021","journal-title":"Cancer Med J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000872","article-title":"The European guidelines on diagnosis and management of neutropenia in adults and children: A consensus between the European Hematology Association and the Eunet-Innochron Cost Action","volume":"7","author":"Fioredda","year":"2023","journal-title":"Hemasphere"},{"key":"B20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"A randomized double-blind multicenter phase iii study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy","volume":"14","author":"Green","year":"2003","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262080-00012","article-title":"Pegfilgrastim","volume":"62","author":"Curran","year":"2002","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221148116","article-title":"Efficacy of same-day versus next-day administration of pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide: A retrospective multi-site analysis","volume":"29","author":"Hobbs","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0166","article-title":"Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer","volume":"18","author":"Alrawashdh","year":"2022","journal-title":"Future Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.6004\/jadpro.2022.13.8.6","article-title":"Meta-analysis of same-day pegfilgrastim administration stratified by myelotoxic febrile neutropenia risk and tumor type","volume":"13","author":"Alrawashdh","year":"2022","journal-title":"J Adv Pract Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s12032-022-01725-9","article-title":"Effect of concomitant use of G-Csf and myelosuppressive chemotherapy on bone marrow and peripheral granulocytes in a mouse model","volume":"39","author":"Endo","year":"2022","journal-title":"Med Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3224","article-title":"The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial","volume":"9","author":"Zhao","year":"2020","journal-title":"Cancer Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1764358\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:21:18Z","timestamp":1776140478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1764358\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":26,"alternative-id":["10.3389\/fonc.2026.1764358"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1764358","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"article-number":"1764358"}}